Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,758 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depression
Interventions: Herbal extract, Sertraline, Lactose monohydrate; Dietary Supplement · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sleep-disordered Breathing, Major Depressive Disorder
Interventions: Positive Airway Pressure (PAP); Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depressive Disorder
Interventions: Sham TMS + Cognitive therapy, Active TMS + Cognitive therapy; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions: L-Dopa, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Major Depression
Interventions: Duloxetine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
Interventions: Amplification of Positivity - Cannabis Use (AMP-C); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Depressive Disorder, Depressive Disorder, Major
Interventions: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more

Conditions: Major Depressive Disorder
Interventions: Quetiapine fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Little Rock, Arkansas • Newport Beach, California • Northridge, California + 34 more

Conditions: Depression, Major Depressive Disorder, Major Depression
Interventions: Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions; Device · Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 19 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Ketamine Hydrochloride, Midazolam injection; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder (MDD), Cognitive Dysfunction
Interventions: Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD), Goal-focused Supportive Contact; Behavioral
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Major Depressive Disorder, Miscarriage, Stillbirth, Neonatal Death
Interventions: Group Interpersonal Psychotherapy (IPT-G), Coping with Depression (CWD); Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Depressive Disorder, Major, Metabolic Syndrome X
Interventions: Pioglitazone; Drug
Lead sponsor: Joseph Calabrese, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder (MDD)
Interventions: amisulpride, placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder (MDD)
Interventions: Ketamine only; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depression
Interventions: Online self-help course plus live follow-up if needed, Online + incentives Follow-up Group; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Social Determinants of Health, Major Depressive Disorder, Cardiovascular Diseases
Interventions: Screening; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Escitalopram; Drug
Lead sponsor: Pharmacology Research Institute; Other
Eligibility: 18 Years to 80 Years
Timeline: Started 2005
U.S. locations: 4
States / cities: Los Alamitos, California • Newport Beach, California • Northridge, California + 1 more

Conditions: Mental Disorder, Substance Use Disorders, Posttraumatic Stress Disorder, Major Depressive Disorder, Anxiety Disorder
Interventions: Individual Placement and Support (IPS), Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR); Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
Interventions: Nitrous oxide gas for inhalation, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depressive Disorder, Major
Interventions: Standard of Care (SOC); Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Search by objective public record fields.

Rhodiola Rosea Therapy of Major Depressive Disorder

Sleep-Disordered Breathing and PAP in Perinatal Depression

Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes

Dopaminergic Dysfunction in Late-Life Depression

Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

Sexual Functioning Study With Antidepressants

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

The Effects of Dopamine on Reward Processing

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

Healthy Mood Internet Intervention Research Project

The Role of Social Determinants in Cardiovascular Health and Vascular Function

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

Supported Employment in Patient Aligned Care Teams

N2O for Acute Suicidality and Depression in the ED

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant